Shantha Biotechnics may shift project out of APIllustrative image – not actual.

Shantha Biotechnics may shift the location of its proposed Rs.60 crore Hyderabad multi product manufacturing facility to outside Andhra Pradesh, following the state government's decision not to buy Indian-made Hepatitis B vaccine for its free immunisation programme funded by the Bill Gates Foundation.

 

Earlier, the state government had called for bids for the supply of the vaccine. Three companies including Shantha Biotechnics and Bharat Biotech from Hyderabad, had responded to the tender. However, Bharat Biotech got involved in a controversy when a police officer suffered complication after being administered the company’s vaccine. This led the state government to decide against using any Indian brands for its programme and asked UNICEF to outsource the vaccine from external parties having World Health Organisation (WHO) certification.

 

However, the managing director of Shantha Biotechnics, Mr K I Varaprasada Reddy, claims that WHO certification is required only for exporting the drug and not for its sale in India as the drug had already been certified by the Drug Controller and endorsed by WHO.

← All latest storiesBack to top →